Comparison
Leuprorelin vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
53714-56-0
197922-42-2
Molecular weight
1209.4 g/mol
3752.13 g/mol
Half-life
3 h
no data
Sequence
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtno data
Mechanism of action
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
4
2
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
3
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Leuprorelin and Teduglutid?
- Leuprorelin is classified as "Research other", while Teduglutid is classified as "Research other". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Teduglutid?
- The highest available evidence level is "Human RCT" for Leuprorelin and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Teduglutid in Germany and the United States?
- Germany: Leuprorelin — Prescription, Teduglutid — Prescription. United States: Leuprorelin — Prescription, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.